Oncology

Moleculin doses first patients in Phase II portion of AML Annamycin combo study

Moleculin Biotech has dosed the first subjects in the Phase II portion of a Phase Ib/II trial evaluating the company’s…

Syndax leukaemia drug hits endpoint goals ahead of planned new drug application

Clinical-stage biopharmaceutical company, Syndax, has announced that it has met one of its goals as part of a Phase I/II…

Pipeline Moves: Advancement prospects plunge for myelodysplastic syndrome drug after trial termination

This week on Pipeline Moves, we kickoff by looking at the terminations of a Phase II trial in myelodysplastic syndrome…

AbbVie’s venetoclax fails Phase III myeloma trial

AbbVie reported negative results from a Phase III CANOVA trial investigating venetoclax in patients with relapsed or refractory multiple myeloma.…

Janssen’s NSCLC combo therapy meets primary endpoint in Phase III trial

The Janssen Pharmaceutical Companies of Johnson & Johnson has reported that the Phase III MARIPOSA clinical trial of Rybrevant (amivantamab-vmjw)…

ImmunoGenesis begins participant dosing in trial of IMGS‑001

ImmunoGenesis has dosed the first participant in its Phase Ia/Ib clinical trial of IMGS-001 for the treatment of relapsed or refractory advanced…

Synthekine doses first subject in Phase Ib of solid tumours trial

Synthekine has dosed the first subject in the Phase Ib portion of a clinical trial of STK-012 to treat solid tumours. The…

Sensei doses first patient in combo therapy arm of trial for SNS-101

Sensei Biotherapeutics has initiated the combination therapy arm of the Phase I/II clinical trial for SNS-101, with the first patient…

Lantern Pharma doses first patient in solid tumour drug trial

US-based artificial intelligence (AI) company Lantern Pharma has dosed the first patient in a Phase I trial of its drug…

Novartis eyes first-line status for its radionucleotide therapy Lutathera

Novartis has announced that the Phase III NETTER-2 trial of the combination therapy of Lutathera (lutetium Lu 177 dotatate) and…